Newly diagnosed diabetes mellitus, DKA, and COVID‐19: Causality or coincidence? A report of three cases

Suwanwongse, Kulachanya; Shabarek, Nehad

doi:10.1002/jmv.26339

Cited by 81 publications

(85 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Epidemiology and clinical manifestations. Diabetic ketoacidosis (DKA) has been observed in patients without known diabetes mellitus weeks to months after resolution of COVID-19 symptoms 182 . It is not yet known how long the increased severity of pre-existing diabetes or predisposition to DKA persists after infection, and this will be addressed by the international CoviDiab registry 183 .…”

Section: Endocrine Sequelaementioning

confidence: 99%

Post-acute COVID-19 syndrome

Nalbandian

Sehgal

Gupta

et al. 2021

Nat Med

3,738

110

3,643

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the coronavirus disease 2019 (COVID-19) pandemic, which has resulted in global healthcare crises and strained health resources. As the population of patients recovering from COVID-19 grows, it is paramount to establish an understanding of the healthcare issues surrounding them. COVID-19 is now recognized as a multi-organ disease with a broad spectrum of manifestations. Similarly to post-acute viral syndromes described in survivors of other virulent coronavirus epidemics, there are increasing reports of persistent and prolonged effects after acute COVID-19. Patient advocacy groups, many members of which identify themselves as long haulers, have helped contribute to the recognition of post-acute COVID-19, a syndrome characterized by persistent symptoms and/or delayed or long-term complications beyond 4 weeks from the onset of symptoms. Here, we provide a comprehensive review of the current literature on post-acute COVID-19, its pathophysiology and its organ-specific sequelae. Finally, we discuss relevant considerations for the multidisciplinary care of COVID-19 survivors and propose a framework for the identification of those at high risk for post-acute COVID-19 and their coordinated management through dedicated COVID-19 clinics.

show abstract

Section: Endocrine Sequelaementioning

confidence: 99%

Post-acute COVID-19 syndrome

Nalbandian

Sehgal

Gupta

et al. 2021

Nat Med

3,738

110

3,643

View full text Add to dashboard Cite

show abstract

“…People with diabetes are at a higher risk for more severe COVID-19 symptoms, hospitalization, and mortality compared with the general population. [1][2][3][4] Recent case reports have associated COVID-19 disease with the onset of type 1 diabetes [5][6][7] ; however, the evidence remains limited and inconsistent. [8][9][10] We developed a highly sensitive and specific test to measure COVID-19 antibodies and applied this assay to people with new-onset and established type 1 diabetes as well as children and adults from the underlying general population during the current pandemic.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of SARS-CoV-2 Antibodies in Children and Adults with Type 1 Diabetes

Jia

Gesualdo

Rasmussen

et al. 2021

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

Objective: As diabetes is a risk factor for severe symptoms, hospitalization, and death with COVID-19 disease, we aimed to assess the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in children and adults with and without type 1 diabetes in Colorado during 2020. Research Design and Methods: We developed a highly sensitive and specific test for antibodies against SARS-CoV-2 and measured the antibodies in children and adults with new-onset (n = 129) and established type 1 diabetes (n = 94) seen for routine diabetes care at our center between January and October 2020. The antibodies were also measured in 562 children and 102 adults from the general population of Colorado. Results: The prevalence of SARS-CoV-2 antibodies in persons with new-onset type 1 diabetes (0.8%; 95% confidence interval 0.1%-4.2%) or those with established disease (4.3%; 1.7%-10.4%) did not differ from that in the general population children (2.8%; 1.8%-4.6%) or adults (3.9%; 1.5%-9.7%). In a subset of individuals with positive antibodies (n = 31), antibodies remained positive for up to 9 months, although the levels decreased starting 3 months after the infection (P = 0.007). Conclusions: From January to October 2020, the prevalence of SARS-CoV-2 antibodies were not different in children and adults with and without type 1 diabetes in Colorado. We found no evidence for increased prevalence of COVID-19 infections among youth with newly diagnosed type 1 diabetes. (COMIRB Protocol 20-1007

show abstract

“…This type of presentation has been reported by many authors ( 3 , 21 , 22 , 23 , 24 , 25 , 26 ) ( 27 ) but its prevalence and features remain poorly researched. A retrospective cohort of 35 patients with COVID-19(T2DM;28, T1DM;5, new presentation;2), presenting with DKA (31·4%), mixed DKA and HHS (37·1%), HHS (5·7%), or hyperglycaemic ketosis (25·7%) were included and evaluated in a study reported from UK ( 21 ).…”

Section: Introductionmentioning

confidence: 70%

“…The requirement of insulin gradually diminished after about 4-6 weeks of diagnosis and then hyperglycemia was controlled with oral anti-hyperglycemic drugs alone ( 23 , 24 ). Another, albeit rarer variety of patients are those who present with new-onset marked hyperglycemia with ketonuria and very mild COVID-19 infection ( 25 , 26 ). The patient, reported by us was managed on small doses of oral anti-hyperglycemic treatment ( 25 ).…”

Section: Introductionmentioning

confidence: 99%